Condition: Small Cell Lung Cancer Extensive Stage · Sponsor: InxMed (Shanghai) Co., Ltd.
This is a multicenter, open-label, Randomized, phase Ib/II clinical study to evaluate the anti-tumor efficacy, safety, tolerability, and PK of IN10018 in combination with anti-PD-1/L1 monoclonal antibody (Tislelizumab is proposed as the combination drug) and chemotherapy (platinum and etoposide) as the first-line treatment in Extensive-stage small cell lung cancer (ES-SCLC).
This description comes directly from the study's public registry record.
Shu Fang · 86-15933968623 · shu.fang@inxmed.com
Lily Li · 86-13911551669 · lily.li@inxmed.com
Always discuss trial participation with your own doctor first.
| Shandong Province Cancer Hospital | Jinan, China | Recruiting |
| Tianjin Medical University Cancer Institute & Hospital | Tianjin, China | Not Yet Recruiting |
| Henan Provincial People's Hospital | Zhengzhou, China | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06030258